CIK 0001690585 · Non-accelerated filer<br>Smaller reporting company
Dianthus Therapeutics, Inc. /DE/
Sign in to watch- Ticker
- DNTH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 929-999-4055
- Business address
- 7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
- Former names
- Magenta Therapeutics, Inc.
- 144 Insider Sale of Securities
- 4 Planned sale Director sold 27,594 shares at $78.05 ($2,153,712)
- 8-K Event Other events
- 144 Insider Sale of Securities
- 4 Option exercise CEO AND PRESIDENT acquired 65,292 shares (option exercise)
- 4 Planned sale CEO AND PRESIDENT sold 122,918 shares at an average $81.49 ($10,016,381)
- 4 Planned sale CHIEF ACCOUNTING OFFICER sold 43,682 shares at an average $81.49 ($3,559,495)
- 4 Planned sale EVP, Head of R&D sold 33,830 shares at $81.48 ($2,756,468)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 8-K Event Material agreement
- 424B5 Offering Prospectus
- S-3MEF Other S-3MEF
- 424B5 Offering Prospectus
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations · Regulation FD disclosure · Other events
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
Page 4 of 33 · 659 filings